Richard L. Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Harry Cassin Managing Editor

Elizabeth K. Spahn Editor Emeritus

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor

FCPA Blog Daily News

« An Open Iran: Normalization dividend with a compliance nightmare | Main | Job: Compliance Officer III - Commercial Banking Group, Lending (San Francisco, CA) »

Pharma news: China restricts hospital drug sales 

China is pushing reforms at public hospitals in the wake of widespread complaints about inadequate healthcare services and corruption related to drug sales.

According to a guideline issued by the State Council, reforms that were piloted in 17 cities in 2010 will be expanded to the country’s 6,800 public hospitals by 2017. The reforms aim to make medical services available to more citizens and reduce drug prices.

As part of the reform package, public hospitals will have to drop drug sales as a major source of revenue and rely more on medical-service charges and government subsidies.

Public hospitals and doctors have relied heavily on drug sales for revenue, resulting in high drug prices and bribery, said Liu Yuanli, dean of Public Health School at Peking Union Medical College. Public hospitals became profit-driven and allied with drugmakers instead of serving the needs of patients, Liu added.

“Public hospitals should be operated for the public good, instead of seeking lucrative gains,” state media Xinhua News said.

The reform guideline requires public hospitals to establish a reasonable drug pricing system.

It also bans public hospitals from setting revenue targets for doctors and connecting their salaries with drugs sales and medical examinations, therefore to eradicate kickbacks and bribes from drugmakers.

The reforms came after a series of bribery scandals involving public hospitals and global drug firms.

In September 2014, a court in China fined UK pharma giant GlaxoSmithKline $490 million following a conviction for bribery.

Sources: Morning Post (北京晨报), Xinhua News, International Business Times


Hui Zhi is the Senior Manager for Content with the China Compliance Digest, where a version of this post first appeared.